Global Interventional Pulmonology Market Report 2021-2025 with Regional Analysis of Bronchoscopy Examination Procedures
20 janv. 2022 05h03 HE
|
Research and Markets
Dublin, Jan. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Interventional Pulmonology Market: Size, Trends & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to...
Insights on the Hospital-Acquired Infection Control Global Market to 2030 - Upsurge in Likelihood of Epidemic or Pandemic Outbreaks is Driving Growth
21 déc. 2021 06h38 HE
|
Research and Markets
Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Hospital-Acquired Infection Control Market by Product & Service and End User: Global Opportunity Analysis and Industry Forecast, 2022-2030" report...
Global Infection Control Market 2021-2026: Surge in Growth for E-Beam Sterilization and Re-Introduction of Ethylene Oxide Sterilization
20 déc. 2021 06h38 HE
|
Research and Markets
Dublin, Dec. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Infection Control Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering. The global infection control...
BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium
29 oct. 2021 15h44 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases...
Global Infection Surveillance Solutions Market is Forecast to Reach $1.03 Billion by 2026, Rising at a CAGR of 15.2%
01 oct. 2021 04h58 HE
|
Research and Markets
Dublin, Oct. 01, 2021 (GLOBE NEWSWIRE) -- The "Global Infection Surveillance Solutions Market by Software (Cloud-based), Service (Product Support, Maintenance, Implementation), End-user (Hospitals...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
29 juin 2021 13h58 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year® 2021 New Jersey Award Finalist
04 juin 2021 13h00 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Global Hospital Acquired Disease Testing Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
27 mai 2021 06h58 HE
|
Research and Markets
Dublin, May 27, 2021 (GLOBE NEWSWIRE) -- The "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
Study identifies high-impact postoperative complications in older patients undergoing hip fracture repair
23 mars 2021 12h00 HE
|
Joint Commission
OAKBROOK TERRACE, Ill., March 23, 2021 (GLOBE NEWSWIRE) -- Hip fracture in older patients is common, debilitating and costly.1,2,3 A new study in the April 2021 issue of The Joint Commission Journal...
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
15 mars 2021 11h12 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...